Ismail Sert,MD,PhDc,FEBS

Associate Prof. of Surgery, HPB and Transplant surgeon, Clinical Researcher, Founder and head of Geriatric Surgery Association

[Erman Akkus @Erman_Akkus]

Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial https://t.co/h4XwQHQ61D

[Syed A. Ahmad @SyedAAhmad5]

THIS IS HUGE. 🔥🔥🔥🔥

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer https://t.co/ujdYR65lUc

[S. George Barreto @sgeorgebarreto]

#earlyonset #colorectalcancer with liver-only metastases
Leveraging real-world data from an Australian Cancer Database (TRACC) - differences in cancer biology, tumour location & treatment sequence on the overall survival of early- vs late-onset patients https://t.co/JYI4PdULU0

[Wojciech Polak @dewojt]

@_ILTS_ Fantastic collaboration between three societies. Thank you #IHPBA for inviting #ILTS

[Giovanni Marchegiani @Gio_Marchegiani]

🧪 Serum CA19.9 in IPMN 🍇 to detect High-Grade Dysplasia and Invasive Carcinoma

🌎 Included in upcoming global GL!

🚨 In 4.6k pts CA19.9 POORLY 🙈 performed in excluding HGD / cancer

👎 No use as standalone / screening test!

🆓 @JAMANetworkOpen

https://t.co/gnTkj3JLfN

[Prof. Dr. Sezai Yılmaz, MD, FACS @profsezaiyilmaz]

‘Yediğimiz peynir-ekmek yaptığımız operasyonlardan çok konuşuldu’ https://t.co/lVpreOKm5q @hurriyetcomtr aracılığıyla

[Giovanni Marchegiani @Gio_Marchegiani]

Postpancreatectomy diarrhoea 🔴🔴 an emerging issue in the era of pancreas cancer surgery

🚨Incidence 33% at 90 days
😖 Severity correlates with QoL
💊 PERT always required + 40% loperamide

✂️ Arterial divestment / vascular resection risk factors

https://t.co/i03eJ7lcQS

[Annals of Surgery @AnnalsofSurgery]

Broad-spectrum antibiotic prophylaxis reduced infectious complications after pancreatoduodenectomy, particularly among patients with preoperative biliary drainage. https://t.co/GSATKOclr7

[Stuart Lichtman, MD, FASCO @smlichtman_md]

Geriatric assessment is the future: Retiring Karnofsky and ECOG perfor... https://t.co/0QlcZnjl7g #asco #asco26 #siog26 #siog #mskcc #gerionc

[Giovanni Marchegiani @Gio_Marchegiani]

Oligometastatic pancreatic cancer 🔴 finally defined in @TheLancetOncol

🥇https://t.co/GEGfvnAy63

🧐 What about treatment?!

😉 Join our ongoing RCT SONAR 📡 https://t.co/TNVpQYDFv1

[Annals of Surgery @AnnalsofSurgery]

Additional resection of initially positive pancreatic neck margin was not found to be associated with oncologic benefits in postneoadjuvant pancreatoduodenectomy for PDAC. https://t.co/ruPzR1TKMa

[Ville Sallinen @villesallinen]

New study from the DISPAIR consortium @BjsOpen!

Refined classification of postoperative pancreatic fistula after left pancreatectomy based on cumulative morbidity.

Open Access: https://t.co/WrnHwaFrhb

[Ville Sallinen @villesallinen]

Hot from the press 🔥🔥🔥
"The @EAHPBA - @ESSOnews - Innsbruck consensus recommendations on peri- and postoperative management following liver resection" out now @hpbjournal. Happy to be able to contribute my small share in this!

https://t.co/iLHkjkGtrv

[Udhayvir Grewal @UGrewalMD]

📝 Pretty cool data with the PUMP2 trial- HAIP for unresectable intrahepatic cholangiocarcinoma. @curecc @TheGutOncLab

48 patients. 22 patients (44%) achieved a PR and 42 patients (84%) disease control at 6 months. 5 patients (10%) converted to resection, of whom one had a pCR.
Median OS was 22.3 months (95% CI, 19.7 to 35.9 months). 1-year OS = 80.0% (95% CI, 69.6% to 91.9%), superior to the historical control of 47% (P < .001). 3-year OS = 31.5% (95% CI, 20.4% to 48.6%).

Definitely something I’ve been offering my patients if eligible. @WinshipAtEmory

https://t.co/dCjyqv8hVK

[Giovanni Marchegiani @Gio_Marchegiani]

👽 Genetically engineered pig-to-human liver xenotransplantation !!!

🇨🇳 First successful auxiliary 🐖 liver xenotransplantation from 🧬 edited pig to a living recipient

no hyperacute or acute rejection… life saving bridge for liver failure ?! 🧐

https://t.co/k5XDlEcGhy

[Sami Akbulut @akbulutsami]

Dünyanın en önemli yayıncı kuruluşu olan Springer, Editörlüğünü ve Yazarlığını yaptığım Kist hidatik hastalığı konulu kitabımı yayınlamıştır. Ülkemiz ve İnönü üniversitesi adına hayırlara vesile olmasını dilerim.

[Giovanni Marchegiani @Gio_Marchegiani]

What is your anticoagulation practice 💉 after portal vein resection in pancreas surgery ?!

🧑‍🧑‍🧒‍🧒 1k pts / 90 days thrombosis 7%

🔮 Predictors resection type / graft material

🩸 Therapeutic anticoagulation 📉 early thrombosis but 👎 at 90 days

https://t.co/16BWrpyt2Q

[Annals of Hepato-Biliary-Pancreatic Surgery @Journal_AHBPS]

A positive resection margin does not determine long-term survival following colorectal liver metastasis resection
🌷https://t.co/8EgiB4rU0f
Ann Hepatobiliary Pancreat Surg 2025 Aug;29(3) Andreas Konstantinou
#Tumor_stage #Nodal_stage #Chemotherapy #Neoadjuvant

[Syed A. Ahmad @SyedAAhmad5]

Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma ⁦@SurgJournal⁩ https://t.co/sGxdE6nIMq

[Annals of Surgical Oncology @AnnSurgOncol]

#AudioVisualAbstract : The Value of #PrimaryTumorResection in Patients with #LiverMetastases : A 10-Year Outcome

https://t.co/Cl2A3ise4r

@NabeelZafarMD
@SyedAAhmad5